The Supervisory Board of BRAIN Biotech AG has appointed Dr. Sven K. Weber to the Executive Board effective October 1, 2026, naming him future Chairman of the Board (CEO). Mr. Adriaan Moelker, who has led the company as CEO for the past six years, will step down on September 30, 2026, and retire as scheduled at the end of his contract term. Mr. Moelker will continue to serve as a senior advisor until January 2027.
Dr. Sven K. Weber (44) brings extensive experience from the BASF Group, where he most recently served as Vice President responsible for the global enzyme business (Global Business Unit Feed Enzymes & Feed Performance Ingredients). In that role, he drove innovation-led, profitable growth, significantly increasing revenue and earnings. Previously, he was Global Segment Director for the automotive OEM business at Chemetall GmbH and headed contract research at hte GmbH in Heidelberg, a provider of high-throughput solutions for R&D workflows. He began his career at Merck Group and holds a diploma in chemistry and a doctorate from the University of Heidelberg, plus an executive program in general management at SGMI Management Institute in St. Gallen.
Dr. Michael Majerus, Chairman of the Supervisory Board, stated: "Over the past six years, Adriaan Moelker has repositioned BRAIN Biotech AG as an integrated manufacturing company in the enzyme sector and has successfully monetized projects from the BRAINBioIncubator. I am now very pleased that, with Dr. Weber, we have brought on board an internationally experienced leader with proven expertise in the industrial enzyme business. He will continue implementing the company’s strategic direction, tap into additional growth potential, and accelerate its operational implementation."
Dr. Weber commented: "I would like to thank the Supervisory Board for the trust they have placed in me. BRAIN Biotech has a strong technological foundation and excellent scientific expertise. Together with the group’s employees, I intend to build on this to accelerate growth, sustainably strengthen profitability, and bring innovative products to market more quickly. My goal is to develop BRAIN into a leading provider of specialty enzymes in selected application areas and to tap into additional growth potential through the BRAINBioIncubator."
This leadership transition is crucial as BRAIN Biotech, a leader in specialty enzymes for food and life sciences, aims to build on its strong foundation. The company operates its own fermentation facilities in the UK and has production sites in continental Europe and the US. In the 2024/25 fiscal year, the group generated revenue of €49.6 million with around 280 employees. For more information, visit the company's website at www.brain-biotech-group.com.
